Evidence map›Paper›PMID 34588856›Full record

ArticleSaudi journal of biological sciences2021

Potential hepatoprotective effects of flavonoids contained in propolis from South Sulawesi against chemotherapy agents.

Muhamad Sahlan, Nur Rizka Alia Hapsari, Kartika Diah Pratami, Apriliana Cahya Khayrani, Kenny Lischer, Alaa Alhazmi, Zuhair M Mohammedsaleh, Abdullah F Shater, Fayez M Saleh, Walaa F Alsanie and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Saudi journal of biological sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Frontiers in pharmacology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Muhamad SahlanDepartment of Chemical Engineering, Faculty of Engineering, Universitas Indonesia, West Java, 16424, Depok, Indonesia.
Nur Rizka Alia HapsariDepartment of Chemical Engineering, Faculty of Engineering, Universitas Indonesia, West Java, 16424, Depok, Indonesia.
Kartika Diah PratamiFaculty of Pharmacy, Pancasila University, 12640 Jakarta, Indonesia.
Apriliana Cahya KhayraniDepartment of Chemical Engineering, Faculty of Engineering, Universitas Indonesia, West Java, 16424, Depok, Indonesia.
Kenny LischerDepartment of Chemical Engineering, Faculty of Engineering, Universitas Indonesia, West Java, 16424, Depok, Indonesia.
Alaa AlhazmiMedical Laboratory Technology Department, Jazan University, Jazan, Saudi Arabia.
Zuhair M MohammedsalehDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk 71491, Saudi Arabia.
Abdullah F ShaterDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk 71491, Saudi Arabia.
Fayez M SalehDepartment of Medical Microbiology, Faculty of Medicine, University of Tabuk, Tabuk 71491, Saudi Arabia.
Walaa F AlsanieCenter of Biomedical Sciences Research (CBSR), Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.
Samy SayedDepartment of Science and Technology, University College-Ranyah, Taif University, B.O. Box 11099, Taif 21944, Saudi Arabia.
Ahmed GaberCenter of Biomedical Sciences Research (CBSR), Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.
University of Indonesia · IDTaif University · SAUniversity of Tabuk · SAJazan University · SAPancasila University · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of doxorubicin and epirubicin as chemotherapy agent causes side effects such as liver damage due to oxidative stress by reactive oxygen species (ROS) that cause increased of ALT and AST level as liver parameter. One source of natural antioxidants as ROS neutralizer comes from flavonoid that contain in propolis. Most researchers claim that flavonoid can be used to protect the liver. The aim of this study was to test the hepatoprotective effect of flavonoid in propolis from South Sulawesi against doxorubicin and epirubicin. The experiment included male Sprague dawley rats divided into nine groups. The rats received the microcapsule propolis or the quercetin orally for 15 days. The hepatotoxicity was promoted by injection epirubicin and doxorubicin (i.v.) with a cumulative dose of 9 mg/kg. In this study, total polyphenol and flavonoid tests of propolis have been carried out, there were 1.1% polyphenols and 2.7% flavonoids, the antioxidant activity tests showed IC50 value of 9849 ppm and LCMS/MS tests supported the presence of phenolic compounds in propolis from South Sulawesi. Liver parameter was measured and the results showed that the propolis 200 mg/kg group produced the lowest ALT and had potential protective effect against doxorubicin and epirubicin-induced hepatotoxicity.

Indexed as

ChemotherapyDoxorubicinEpirubicinFlavonoidHepatoprotectivePropolis

Identifiers

PMID34588856
PMCPMC8459154
OpenAlexW3193529854

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.